source
- FDA plans study on barriers to women's enrollment in pregnancy exposure registries and announces PRV fee ratesThe Food and Drug Administration said it will conduct research into perceived barriers that limit women’s participation in pregnancy exposure registries. It also released the fee schedule for prio…
- FDA grants three-month review extension for Exelixis' metastatic colorectal cancer candidateExelixis, a California drug developer, has provided the FDA with additional safety and efficacy data for its experimental therapy aimed at treating metastatic colorectal cancer. The agency respond…